Lercanidipina Farmoz (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth muscle, reducing calcium entry into the cells. This causes arterial vasodilation, decreases peripheral vascular resistance, and ultimately lowers systemic blood pressure.

The appropriate dose of Lercanidipina Farmoz is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions exactly.

Safety of lercanidipine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering potent arterial vasodilation with a relatively low effect on heart rate. Compared with ACE inhibitors or beta‑blockers, it may cause fewer cough or fatigue symptoms but can be associated with peripheral edema and flushing.

Store Lercanidipina Farmoz at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, light, and excessive heat to maintain product stability.

Lercanidipina Farmoz is taken orally as a tablet. It should be swallowed whole with a glass of water, with or without food, as directed by the prescribing clinician.

Serious adverse events, although rare, include severe hypotension, angio‑edema (rapid swelling of the face, lips, tongue or throat), and myocardial infarction. Patients should seek immediate medical attention if they experience symptoms such as fainting, severe dizziness, swelling of the airway, or chest pain.

Lercanidipina Farmoz should be avoided in individuals with known hypersensitivity to lercanidipine or any excipients, and in patients with severe aortic stenosis or uncontrolled hypotension. Caution is also advised for the elderly and those with significant liver impairment.